393 related articles for article (PubMed ID: 29470642)
1. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.
Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M
Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517
[TBL] [Abstract][Full Text] [Related]
3. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
4. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
5. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
6. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives.
Boutou AK; Pitsiou G
Expert Opin Pharmacother; 2020 Jul; 21(10):1145-1155. PubMed ID: 32089012
[TBL] [Abstract][Full Text] [Related]
8. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
[TBL] [Abstract][Full Text] [Related]
9. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
11. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Garnock-Jones KP
Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
[TBL] [Abstract][Full Text] [Related]
12. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
13. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
14. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
[TBL] [Abstract][Full Text] [Related]
15. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
16. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
18. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
19. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
[TBL] [Abstract][Full Text] [Related]
20. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]